Quercetin and taxifolin inhibits TMPRSS2 activity and its interaction with EGFR in paclitaxel‐resistant breast cancer cells: An in silico and in vitro study
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Durga Bhavani Kundrapu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology, Department of Life Sciences, GITAM School of Science, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, India. Hauptthemen laut MEDLINE: Quercetin, ErbB Receptors, Drug Resistance, Neoplasm, Paclitaxel. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 110 Literaturangaben.
Abstract (Originalsprache)
Transmembrane protease/serine (TMPRSS2), a type II transmembrane serine protease, plays a crucial role in different stages of cancer. Recent studies have reported that the triggering epidermal growth factor receptor (EGFR) activation through protease action promotes metastasis. However, there are no reports on the interaction of TMPRSS2 with EGFR, especially in triple‐negative triple negative (TNBC). The current study investigates the unexplored interaction between TMPRSS2 and EGFR, which are key partners mediating metastasis. This interaction is explored for potential targeting using quercetin (QUE) and taxifolin (TAX). TMPRSS2 expression patterns in breast cancer (BC) tissues and subtypes have been predicted, with the prognostic significance assessed using the GENT2.0 database. Validation of TMPRSS2 expression was performed in normal and TNBC tissues, including drug‐resistant cell lines, utilizing GEO datasets. TMPRSS2 was further validated as a predictive biomarker for FDA‐approved chemotherapeutics through transcriptomic data from BC patients. The study demonstrated the association of TMPRSS2 with EGFR through in silico analysis and validates the findings in TNBC cohorts using the TIMER2.0 web server and the TCGA dataset through C‐Bioportal. Molecular docking and molecular dynamic simulation studies identified QUE and TAX as best leads targeting TMPRSS2. They inhibited cell‐free TMPRSS2 activity like clinical inhibitor of TMPRSS2, Camostat mesylate. In cell‐based assays focused on paclitaxel‐resistant TNBC (TNBC/PR), QUE and TAX demonstrated potent inhibitory activity against extracellular and membrane‐bound TMPRSS2, with low IC 50 values. Furthermore, ELISA and cell‐based AlphaLISA assays demonstrated that QUE and TAX inhibit the interaction of TMPRSS2 with EGFR. Additionally, QUE and TAX exhibited significant inhibition of proliferation and cell cycle accompanied by notable alterations in the morphology of TNBC/PR cells. This study provides valuable insights into potential of QUE and TAX targeting TMPRSS2 overexpressing TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology, Department of Life Sciences, GITAM School of Science, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, India.
- Department of Life Sciences, GITAM School of Science, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, India.
ORCID-Profile: RamaRao Malla
Zitieren
APA
Kundrapu, D. B., Chaitanya, A. K., Manaswi, K., Kumari, S., & Malla, R. (2024). Quercetin and taxifolin inhibits TMPRSS2 activity and its interaction with EGFR in paclitaxel‐resistant breast cancer cells: An in silico and in vitro study. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14600
Vancouver
Kundrapu DB, Chaitanya AK, Manaswi K, Kumari S, Malla R. Quercetin and taxifolin inhibits TMPRSS2 activity and its interaction with EGFR in paclitaxel‐resistant breast cancer cells: An in silico and in vitro study. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14600
BibTeX
@article{Kundrapu2024,
author = {Kundrapu, Durga Bhavani and Chaitanya, Amajala Krishna and Manaswi, Kothapalli and Kumari, Seema and Malla, RamaRao},
title = {Quercetin and taxifolin inhibits TMPRSS2 activity and its interaction with EGFR in paclitaxel‐resistant breast cancer cells: An in silico and in vitro study},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14600}
}
EUVIMED